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Abstract 
The binding of ‘%labele,d insulin-like growth factor-II (‘%GF-II) to luminal and basolateral membrane vesicles isolated from pars 
convoluta and the straight part (pars recta) of rabbit proximal tubule was investigated. Analyses of the binding data by use of the general 
stoichiometric binding equation revealed, that in all reparations IGF-II was bound to one high-affinity binding site and other sites with 
lower affinities. The specificity of the high-affinity 
! ’ ‘I-IGF-II binding to the membrane vesicles assessed by displacement by unlabeled 
IGF-II, IGF-I and insulin showed that IGF-I displaced ‘zI-IGF-II in the range 22.5-47.9 nM (IC,,) whereas insulin did not effect 
‘251-IGF-II binding at all. P-,Galactosidase inhibited the 125 I-IGF-II binding with half-maximal inhibition of 20-30 nM /3-galactosidase. 
D-Mannose 6-phosphate increased the binding of ‘=I-IGF-II and reversed the inhibitory effect of P-galactosidase. Analyses of ‘2sI-IGF-II 
binding curves in the presence of /I-galactosidase or D-mannOSe 6-phosphate demonstrated that none of these compounds changed the 
binding affinity of ‘zI-IGF-II for the membrane vesicles. The IGF-II/M6P receptor content in the luminal membranes was in the range 
0.21-0.34 pmol IGF-II/MBF’ receptor per mg protein and very low compared to 2.27-2.86 pmol IGF-II/M6P receptor per mg protein in 
basolateral membranes. 
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1. Introduction 
The IGF-II receptor and the cation-independent man- 
nose 6-phosphate receptor are the same protein (the IGF- 
II/M6P receptor) [l]. The cation-independent mannose 
6-phosphate receptor plays a role in transport of soluble 
glycoproteins synthesized in the endoplasmic reticulum [2] 
whereas in the membrane the IGF-II/M6P receptor func- 
tion is to internalize exolgenous lysosomal enzymes and 
IGF-II [2,3]. In contrast to M6P lysosomal enzymes impair 
the IGF-II binding, and IGF-II inhibits lysosomal enzyme 
binding [1,4-61. However, the molecular mechanism of 
this effect is still a controversial question [5,7]. Another 
aspect, which is still disputed, is whether the receptor 
Abbreviations: IGF-II, insulin-like &rowth factor-II; IGPBP, IGF- 
binding proteins; M6P, Dmannose 6-phosphate; IGF-II/M6P, insulin-like 
growth factor II/Dmannose 6-Phosphate. 
* Corresponding author. E-mail: cj@biokemi.aau.dk. Fax: +45 
86131160. 
mediates signal transduction or only functions in the trans- 
port of lysosomal enzymes, IGF-II, and other ligands [2]. It 
has been suggested that IGF-II/M6P receptor has two 
distinct signaling functions that positively or negatively 
regulate the activity of GTP-binding protein (Gail in 
response to IGF-II or M6P [8,9]. Likewise, a possible role 
in signal transduction by increasing inositol triphosphate 
also has been reported for renal proximal tubular basolat- 
era1 membranes from mongrel dogs [lo]. 
The majority of cellular IGF-II/M6P receptor has been 
reported to be localized intracellularly whereas only a 
smaller proportion of the total receptor pool is at the cell 
surface [3]. Examination of the latter by vesicle studies 
showed that the IGF-II/M6P receptors are distributed 
symmetrically in luminal and basolateral membranes from 
the proximal tubule of mongrel dog kidney. By contrast, 
similar experiments revealed that the IGF-I receptors are 
located primarily at the basolateral cell membrane [ll]. 
Likewise, we have previously reported a lo-fold higher 
binding capacity for IGF-I to basolateral than to luminal 
membrane vesicles isolated from either the convoluted part 
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(pars convoluta) or the straight part (pars recta) of rabbit 
proximal tubule [12]. These findings correspond to results 
obtained by electron microscope autoradiography of iso- 
lated, perfused proximal tubules after basolateral exposure 
1121. However, recent studies on rat renal cells have indi- 
cated that the IGF-II/M6P receptor is located primarily in 
the pars convoluta and mainly in components of the vacuo- 
lar system in the apical cytoplasm of the proximal convo- 
luted tubule cells [13]. Evidently, there seems to exist a 
discrepancy in the observations of the renal IGF-II/M6P 
receptor distribution in luminal and basolateral mem- 
branes. In addition, the segmental localization of the recep- 
tors in the proximal tubule needs to be further examined 
since it is rather puzzling that the IGF-II/M6P receptors 
should be confined only to the pars convoluta and not the 
pars recta. Thus, the purpose of the present study was to 
examine the distribution of IGF-II binding and IGF- 
II/M6P receptors in luminal and basolateral membranes 
from the pars convoluta and pars recta of rabbit proximal 
tubule. The presence of IGF-II/M6P rece 
fied by studying the displacements of 4 
tors was veri- 
’ ‘I-IGF-II with 
unlabelled IGF-II, IGF-I and insulin. Furthermore, the 
interactions of M6P and P-galactosidase with the ‘251-IGF- 
II binding to the receptor in membrane associated environ- 
ments were investigated. 
2. Material and methods 
2.1. Materials 
(3-[1251]Iodotyrosyl)insulin-like growth factor-II (1251- 
IGF-II) with a specific activity of 2000 Ci/mmol 
(purchased from Arnersham International, Amersham, 
Bucks, UK) was used in all experiments. Unlabeled bio- 
synthetic IGF-I and IGF-II were purchased from Bachem 
Bioscience, Bubendorf, Switzerland, unlabeled insulin was 
obtained from Novo-Nordisk A/S, Bagsvard, Denmark. 
/3-Galactosidase (EC 3.2.1.23) isolated from bovine testes 
with activity of 3.0 U/mg (one unit will hydrolyze 1.0 
pmol of o-nitrophenyl-P-o-galactoside to o-nitrophenol 
and n-galactose per min at pH 4.4 at 25” C) and rr-mannose 
6-phosphate were obtained from Sigma, St. Louis, MO, 
USA. 
2.2. Preparation of luminal and basolateral membrane 
vesicles from pars convoluta and pars recta of rabbit 
proximal tubule 
Adult male and female rabbits weighing approx. 3-4 kg 
were killed by a blow to the neck, exsanguinated and the 
kidneys were excised as previously described [14,15]. Lu- 
minal and basolateral membrane vesicles were isolated 
from pars convoluta (cortex corticis) and from pars recta 
(outer stripe of outer medulla) of the proximal tubule as 
previously described [15]. Briefly, the outer cortical tissue 
was obtained by taking slices < 0.4 mm thick from the 
surface of the kidney. Strips of outer medulla approx. 1 
mm thick (representing predominantly pars recta) were 
dissected from outer stripe of outer medulla. The tissue 
was homogenized and luminal and basolateral vesicles 
were prepared by differential centrifugation and by Mg*+ 
precipitation analogous with Ca*+ precipitation as de- 
scribed in [1.5]. The purity of the membrane vesicle prepa- 
rations was examined by electron microscopy and by 
measuring specific activities of various enzyme markers 
[14]. The activities of the enzyme markers in the luminal 
membrane vesicle fractions were enriched as compared 
with the corresponding homogenates by the following 
factors (n = 15): 12.4 f l.&fold (alkaline phosphatase), 
31.5 + 2.7-fold (leucine aminopeptidase), and 9.4 f 2.4- 
fold (maltase). Average enrichments in specific activity of 
the basolateral marker, Na+/K+-stimulated ATPase, and 
that of the mitochondrial marker, succinate dehydrogenase, 
were in all cases < 0.4 and < 0.04, respectively. The 
amount of protein was determined as described by Lowry 
et al. [16] with modification as described by Peterson [17] 
and using bovine serum albumin as a standard. All solu- 
tions used in this study were sterilized before use. 
2.3. Binding studies 
Membrane vesicles prepared from the four regions, i.e., 
luminal and basolateral membrane vesicles from pars con- 
voluta and pars recta, respectively, were tested for radiola- 
beled IGF-II binding. The protocol for binding experi- 
ments were essentially as described previously [12]. Bind- 
ing experiments were performed in duplicate in 1.5 ml 
polypropylene microfuge tubes. The buffer system was a 
HBS buffer consisting of 140 mM NaCl, 5 mM KCl, 5.5 
mM CaCl,, 10 mM Hepes, 10 mM glucose, 1% BSA, 
0.01% bacitracin, and unless otherwise stated pH 7.1. The 
incubation mixture consisted of 50 ~1 membrane suspen- 
sion, 425 ~1 of buffer solution with unlabeled peptide or 
other competitive or non-competitive agent or buffer alone, 
and 25 ~1 of ‘251-IGF-II (approx. 10-l’ M, 20000-30000 
cpm). The final protein concentration in basolateral and in 
luminal membrane suspension were 0.1 and 1 mg/ml, 
respectively. Following 20 h incubation at 4” C membrane 
bound, radiolabeled peptide was separated from free pep- 
tide by centrifugation (7500 X g, 5 min) in a Beckman 
Microfuge B. The supernatant was aspirated and the tube 
and the pellet were gently washed with ice-cold binding 
buffer (0.5 ml). The tip of the tube with the pellet was cut 
off and bound and free fractions were counted in a LKB, 
Wallac y-counter. The specific bindin 
Q 
was calculated as 
the difference between the amount of ’ ‘I-IGF-II bound in 
the absence (total binding) and the presence of 1 PM 
unlabeled IGF-II (non-specific binding). The degradation 
of the tracer in the incubation medium was routinely 
checked at the end of the incubation period by recipita- 
tion with 15% (wt/vol> TCA. Degradation of ’ P 51-IGF-II 
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was 11% (luminal convoluta), 8% (luminal recta), 5% 
(basolateral convoluta) and 5% (basolateral recta) after 
incubation of the membranes 20 h at 4” C. The optimal 
conditions for ‘251-IGF-II binding to luminal and basolat- 
era1 membrane vesicles occurred after incubation for 20 h 
at pH 7.1 at 4” C. Accordingly all binding studies were 
conducted at 20 h at pH 7.1 at 4” C. 
2.4. Binding parameters 
The general stoichiometric binding equation may be 
formulated as: 
K,c + 2K,K2c2 + . ..+ NK,K,...K,cN 
r= 
l+K,c+K,K,c*+ . ..+K.K2...KNcN (1) 
where r = average number of moles of ligand bound per 
mol of protein ((ligand),,,,,/(Pr),,,,,); c = equilibrium 
concentration of ligand ([l&and]); N = the maximum value 
of r, i.e., when c + ~0. krj = stoichiometric binding con- 
stant for step j as described by Adair and Klotz (see Ref. 
[18]). The equation can be transformed into: 
N 
r= C 
cKj 
j=1 l+cKj (2) 
Simplifying Eq. (2) to only two terms, the equation is 
equivalent to a two sites binding model: 
IGF-II,,,, = 
G’rhtaJG [IGF-111 
1 + K, [ IGF-II] 
+ n2(Prhota’ K,[IGF-111 
1 + K:: [IGF-II] 
Equivalent to: 
(3) 
IGF-II,,,, = 
B,,, .I [IGF’-111 4nax.2 WF-III 
~~~~~~~ + [IG~F-II] + ~~~~~~~ + [IGF-II] 
(4) 
Kdiss, = stoichiometric dissociation constant. The equation 
is sometimes named a two terms Scatchard. In this case 
B max.1 and Bmax.2 denote the concentrations of binding 
sites. In case of N = 1 etquivalent to a one site binding 
model the above equation is further simplified: 
IGF-II,,,,, = 
B,,, [IGF-II] 
Kdiss + [IGF-II] (5) 
The Eqs. (4) and (5) were fitted to the data by finding 
the parameters, i.e., B,,,, Kdiss, (Eq. 5) or Bmax.lr Kdiss.1, 
B max,2, Kdiss,* (Eq. (4) that cause the equations to best fit 
the data using nonlinear regression. Iterations were contin- 
ued until minimum of squares of the residuals were reached. 
The norm represents the closeness of the fit of the itera- 
tion. Numerically, it is the square root of the sum of 
squares of the residuals. 
2.5. Competitive binding parameters 
A-D 
IGF-II,,,, = 
1+ (LwI~50)B 
+D 
Eq. (6) is a four parameter logistic function describing a 
sigmoid curve. X is the concentration of unlabeled dis- 
placer. The parameters A is the maximal radioligand 
binding, i.e., when X is zero; D is the minimal radioli- 
gand binding, i.e., X--f m. B is the slope, and IC,, refers 
to the inflection point and thus to the concentration of 
unlabeled compound displacing 50% of the radiolabeled 
binding. A, B, D, and IC,, were estimated by non-linear 
curve fitting. 
The IC,, values estimated from Eq. (6) were used for 
calculating the K,, the dissociation constant of displacer 
by using the Cheng-Prusoff equation [19]. 
Ic,, = K,(I + [IGF-II * I/K,) (7) 
IC,, is the concentration of the unlabeled compound that 
displaces 50% of radiolabeled ligand binding. [IGF-II * ] is 
the concentration of the radiolabeled compound. K, is the 
dissociation constant of radiolabeled compound. 
3. Results 
3.1. IGF-II binding to luminal and basolateral membrane 
vesicles 
Luminal and basolateral membrane vesicles from pars 
convoluta and pars recta of rabbit proximal tubules were 
tested for IGF-II binding. Fig. 1 displays binding of IGF-II 
at a fixed membrane protein concentration. Unless other- 
wise stated the data are representative of at least three 
experiments, each performed in duplicate on separate occa- 
sions. The binding data obtained by luminal and basolat- 
era1 membrane vesicles from pars recta are illustrated in a 
direct (inset) and a Scatchard plot. The binding data were 
analyzed by the two terms stoichiometric binding equation 
by using least-squares non-linear regression to a one site 
(Eq. (5)) or a two-sites binding model (Eq. (4)) [18]. Table 
1 summarizes the binding parameters obtained by the 
approximations and the norm value, which represents the 
closeness of the fit of the iterations. The plots reveal that 
IGF-II binds to more than one site since a one site model 
should result in a straight line in the Scatchard plot. This is 
supported by the direct binding curves (inset) showing that 
no saturation phenomenon were obtained in any of the 
cases. It is seen from the Table that Kdiss,l parameters are 
within a range from 1 to 1.6 nM. As expected the norm 
values shown in Table 1 were essentially lower for a 
two-sites model compared to a one-site model. The curves 
seen in Fig. 1 have been drawn only on the basis of the 
parameters estimated by the two-sites binding model (Eq. 
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Table 1 
IGF-II binding to luminal and basolateral membrane vesicles 
Vesicles from: 
Pars convoluta luminal 
Pars recta luminal 
Pars convoluta basolateral 
Pars recta basolateral 
B mar.1 Kdiss.1 
0.21 1.14 
0.34 1.64 
2.86 1.63 
2.27 1.00 
B Dux.Z Kdiss.2 
58.3 1185 
175 5748 
166 1001 
55 154 
Norm (Eq. (5)) 
0.356 
0.471 
3.55 
2.83 
Norm (Eq. (411 
0.244 
0.260 
1.92 
1.04 
Binding parameters, B,,,, (pmol/mg) and Kdiss. (nM), were obtained by using nonlinear regression of Eqs. (5) and (4) to the experimental ‘251-IGF-II 
binding data. 
(4)). It should be emphasized that the binding parameters, 
B max,,, Kdiss,l, Bmax,2 and Kdiss,2 are a set of constants 
causing the stoichiometric binding equation to fit the ex- 
perimental data using nonlinear regression [l&20]. The 
dotted lines in Scatchard plot illustrate the high-affinity 
binding to the membranes and were drawn using the 
constants, Kdiss,l and Bmax,l given in Table 1. If Bmax.l 
corresponds to the high-affinity IGF-II/M6P receptor site 
concentration, as supported by the experiments described 
in the following, it means that luminal and basolateral 
membranes from pars recta contains 0.34 pmol and 2.27 
pmol IGF-II/M6P receptor per mg protein, respectively. 
The corresponding values for luminal and basolateral 
membranes from pars convoluta were 0.21 pmol/mg and 
2.86 pmol/mg. 
3.2. Effects of IGF-I and insulin on IGF-II binding to 
luminal and basolateral membrane vesicles 
In a series of experiments, we examined the specificity 
of the 1251-IGF-II binding by measuring the displacement 
of radiolabeled IGF-II bound to luminal and basolateral 
membrane vesicles at increasing concentrations of unla- 
beled IGF-II, IGF-I or insulin in order to differentiate 
between the binding of IGF-II to IGF-II/M6P receptor 
and to other proteins. The results shown in Fig. 2 are from 
pars recta. The maximal ‘251-IGF-II binding was set to 
100%. The IC,, values for IGF-II and IGF-I are summa- 
rized in Table 2. The ICY,, values by homologous displace- 
ment by IGF-II were in the range 0.88-1.37 nM. By 
homologous displacement, the K, = K,, and since the 
tracer 1 ‘I-IGF-II concentration is known (0.01 nM), this 
gives by insertion in Eq. (7) a Kd = 1.0 nM. This value is 
Table 2 
Specificity of lZSI-IGF-II binding 
close to the mean value of the high-affinity constant 
estimated by a two terms stoichiometric binding equation. 
Furthermore, Fig. 2 and Table 2 show IC,, values of IGF-I 
in the range 22.5-47.9 nM with a mean value of 31.3 nM. 
By contrast, insulin even at a high concentration of 1 PM 
did not affect the 1251-IGF-II receptor interaction. The 
figures clearly demonstrate that the ‘251-IGF-II is bound 
with high affinity to IGF-II/M6P receptors in both lumi- 
nal and basolateral membranes as IGF-I displaced ‘*‘I- 
IGF-II, but insulin did not effect ‘251-IGF-II binding at all. 
3.3. Effects of P-galactosidase and o-mannose 6-phos- 
phate on 1251-IGF-II binding to IGF-II/M6P receptors 
We examined the inhibitory effect of /3-galactosidase 
on the 1251-IGF-II binding to membrane vesicles by addi- 
tion of increasing concentrations of P-galactosidase to the 
incubation mixture. In Fig. 3, the inset shows the data 
obtained by basolateral membrane vesicles from pars recta, 
but virtually similar patterns were obtained by the other 
membrane preparations (not shown). Binding of 1251-IGF-II 
is expressed as a percentage of stock input radioactivity 
(25 000 cpm; concentration 27 PM), giving a total binding 
of 18% and a binding of 4.5% in the presence of 100 nM 
IGF-II. The concentration of P-galactosidase which under 
these conditions was required for half-maximal inhibition 
was determined from the curve as 20.5 nM. Likewise, 
half-maximal inhibition was found to be 20-30 nM /3- 
galactosidase for the other membrane preparations (not 
shown). We found no differences in the results obtained by 
diverse batches of commercial available P-galactosidase 
from bovine testes. The inhibitory effect of P-galacto- 
sidase on 1251-IGF-II binding was subsequently studied 
IGF-II; IC,, (nM) IGF-I; IC,, (nM1 Insulin Norm (Eq. (61) 
Vesicles from: 
Pars convoluta luminal 0.88 31.1 no dis. 10.3 ; 7.26 
Pars recta luminal 0.98 47.9 no dis. 6.88; 12.5 
Pars convoluta basolateral 1.37 23.7 no dis. 12.9 ; 7.55 
Pars recta basolateral 0.90 22.5 no dis. 10.3 ; 8.74 
The specificity of the binding to membrane vesicles was assessed by displacement by unlabeled IGF-II, IGF-I and insulin. 
no dis., no displacement. 
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more closely. To clari probable changes in high-affinity 
binding a number of 
f? ’ 51-I~GF-II binding isotherms in the 
presence of inhibiting concentrations of /3-galactosidase 
[IGF-II] (dd) 
‘0 0 1 2 3 
m Bound IGF-II (pmol) 
N 0 
r’ B Basolateral 
a 
2 
ot, ,i,, , , , , , , , , , , , , 
0 2 4 6 8 io 12 14 16 
: Bound IGF-II (pmol) 
Fig. 1. Concentration dependence of IGF-II binding to vesicles isolated 
from luminal and basolateral membranes from pars recta of rabbit proxi- 
mal tubule, depicted as Scatchard plot or as direct plots in insets. The 
incubation mixtures consisted of !iO ~1 membrane suspension, 425 ~1 of 
buffer solution with unlabeled peptide or other competitive or non-com- 
petitive agent or buffer, and 25 ~1 of ‘251-IGF-II (approx. 10-i’ M, 
20000-30000 cpm). Final protein concentrations were 0.1 mg/ml 
(basolateral) and 1 mg/ml (luminal) membrane suspension. After 20 h 
incubation at 4” C membrane bound, radiolabeled peptide was separated 
from free peptide by centrifugation. The specific binding was calculated 
as the difference between the amount of IGF-II bound in the absence 
(total binding) and the presence of 1 FM unlabeled IGF-II (non-specific 
binding). The lines through the points were drawn by approximating the 
binding data by using least-squar,es non-linear regression to a two terms 
stoichiometric binding equation (Eq. (4)). The data comprise of least 
three set of experiments, each perform in duplicate on separate occasions. 
Mean values + SD., are given. (A) Luminal membrane vesicles from pars 
recta; (B) basolateral membrane vesicles from pars recta. 
A Luminal 
120 - 
E 
;100 - 
2 60- 
: 
i 60- 
I 
2 40- 
I loo-ll 
I I I I I I 
lo-lo 10-a 10-a 10-T 10-s 10-s 
Peptide concentration (M) 
B Basolateral 
120 
E c 
- 100 - 
z 
? 66- 
S 
=I 
60 - 
& 40- 
H 
0 
insulin 
,! 20- 
: rl 0 I 
1o-” 1o-‘o 1o-v 1o-a 10-r 1o-a 1o-” 
Peptide concentration (M) 
Fig. 2. Displacement of (3-[‘251]iodotyrosyl)IGF-II bound to luminal and 
basolateral membrane vesicles by increasing concentrations of unlabeled 
IGF-II, IGF-I and insulin. The maximal ‘251-IGF-II binding was set to 
100%. Values are means of three set of experiments. (A) Luminal 
membrane vesicles from pars recta, (B) basolateral membrane vesicles 
from pars recta. 
were generated. Fig. 3 shows binding of ‘251-IGF-II in the 
presence of 0 nM, 30 nM and 100 nM /3-galactosidase to 
basolateral membrane vesicles from pars recta. Non-linear 
curve fitting of the data to Eq. (6), gave IC,, values of 
1.57 nM, 1.80 nM and 2.30 nM, respectively. In another 
set of experiments with basolateral membrane vesicles 
from pars convoluta curve fitting revealed values 1.31 nM, 
1.25 nM and 1.29 nM, respectively (not shown). All in all 
we did not observe any significant change in dissociation 
constant with increasing P-galactosidase. 
The influence of M6P on the I25 I-IGF-II binding to 
IGF-II/M6P receptor was examined and a representative 
experiment is shown in Fig. 4. The maximal binding of a 
standard preparation was in this case 17% of added 1251- 
IGF-II. By increasing concentrations of M6P the binding 
reached a level of 30% at approx. 1 mM M6P (upper 
curve). Half-maximal activation was calculated to 72 PM 
D-mannose 6-phosphate. The combined influence of /3- 
galactosidase and o-mannose 6-phosphate on the IGF-II 
binding was investigated and shown in the lower curve. In 
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Peptide concentration (M) 
Fig. 3. Inhibitory effect of P-galactosidase on the 1251-IGF-II binding to 
basolateral membrane vesicles. Binding of 1251-IGF-II is expressed as 
percentage of input radioactivity (25000 cpm; concentration 27 pM) at 
three separate P-galactosidase concentrations: 0 nM (a), 30 nM (v) and 
100 nM ( W) by increasing concentrations of unlabeled IGF-II or by 
increasing concentrations of P-galactosidase as shown in inset. 
these cases 100 nM P-galactosidase were included in all 
samples. The figure shows that the inhibition of ‘251-IGF-II 
binding by /3-galactosidase was reversed to approximately 
the starting value by M6P and completely abolished by a 
M6P concentration of 0.1 M. 
The increase in ‘251-IGF-II binding to the receptor in 
the presence of 0 mM, 0.1 mM and 5 mM D-mannose 
6-phosphate are shown in Fig. 5. The binding data were 
fitted to Eq. (61, and IC,, values calculated. All prepara- 
tions showed a significant stimulation in ‘251-IGF-II bind- 
ing. In the presence of 5 mM M6P the binding was 
increased from 20% to 30% for basolateral membrane 
preparations. The obtained IC,, values were virtually iden- 
tical. This indicates that the M6P stimulation effect did not 
10-e 1o-5 lo-’ 1o-s lo+ 10-l 
D-mannose 6-phosphate (M) 
Fig. 4. Activation effect of M6P on 1251-IGF-II binding to basolateral 
membrane vesicles. Representative experiments showing binding of 1251- 
IGF-II is expressed as percentage of radioactivity (curve 1). Reversal of 
the inhibitory effect of pgalactosidase with M6P. In these experiments 
100 nM P-galactosidase was included in all samples (curve 2). 
mY YBP 
.I mY YBP 
mu Y8P 
Fig. 5. ‘251-IGF-II binding in the presence of mmannose 6-phosphate. 
Binding curves in the presence of 0 mM, 0.1 mM, and 5 mM M6P by 
increasing concentrations of unlabeled IGF-II are shown. The binding 
data are fitted to Eq. (61, the four parameter logistic function. 
influence the affinity of IGF-II for the IGF-II/M6P recep- 
tor. 
4. Discussion 
Hammerman and Rogers observed an asymmetrical dis- 
tribution of IGF-I receptors in isolated basolateral and 
brush-border membranes from mongrel dog kidney with 
localization being primarily on the basolateral side, whereas 
they found a symmetrical binding of ‘251-IGF-II in both 
types of membranes [ll]. A recent study on rat renal cells 
claims that IGF-II/M6P receptors are located predomi- 
nantly in pars convoluta and mainly in components of the 
vacuolar system in the apical cytoplasm of the proximal 
convoluted tubule cells [13]. Thus, the purpose of the 
present study was to examine the distribution of IGF-II 
binding and IGF-II/M6P receptors in luminal and basolat- 
era1 membranes from pars convoluta and pars recta of 
rabbit proximal tubule. The binding curves illustrated in 
Fig. 1 and the corresponding values given in Table 1 
revealed that a saturation level of IGF-II was never ob- 
tained. Consequently, it seems reasonable to conclude that 
IGF-II binds to more than one binding site. This is in 
accordance with our previous results which demonstrated 
that both luminal and basolateral membranes possess IGF-I 
receptors which, in addition to IGF-I, competitively bind 
IGF-II [12]. As mentioned previously, the binding parame- 
ters, Bmax.l, Bmax.2, Kdiss.1 and Kdiss.2 are one set of 
constants that causes the stoichiometric binding equation 
to fit the experimental data [18,20]. Expressed in Scatchard 
equation, Bmax.1 and Bmax.2 denote the concentrations of 
the first and following binding sites, respectively, and 
Kdiss.l is the high-affinity dissociation constant. Further- 
more, it is evident from Fig. 1 and 2 that Kdiss.l represents 
the high-affinity IGF-II binding to IGF-II/M6P receptor 
as the relative potencies of IGF-II, IGF-I and insulin are in 
accordance with the characteristic of the affinities of these 
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ligands [1,21,22]. However, the binding patterns cannot 
definitely exclude the possibility that part of IGF-II is 
bound to IGF-binding proteins (IGFBPs), as IGFBPs 
(IGFBP-1, IGFBP3, IGFBP4) are characterized by bind- 
ing IGF-I and IGF-II with almost same affinity or IGF-II 
with higher affinity than IGF-I (IGFBP-2, IGFBPJ, 
IGFBP-6) and do not bind insulin at all [23,24]. It should 
be noticed that the Kdiss,, dissociation constant can be 
determined from either the. direct plot or calculated from 
competition curves cf. Fig. 2, as the latter primarily repre- 
sent the high-affinity binding. On the basis of Bmax.r we 
conclude that the IGF-II/M6P receptor is asymmetrically 
distributed with 2.27 pmol/mg in basolateral membranes 
compared to 0.34 pmol/mg in luminal membranes from 
pars recta. Approximately same values of Bmax,r was 
found for luminal membranes from pars convoluta (data 
not shown) indicating that the IGF-II/M6P receptor con- 
tent in luminal membranes of rabbit proximal tubule in 
either cases is very low, almost negligible. The low con- 
tent of IGF-II/M6P receptors in both luminal and basolat- 
era1 membranes could explain why immunolabeling and 
autoradiographic techniques were not able to detect any 
IGF-II/M6P receptors in rat renal membranes, but only in 
the vacuolar system in the apical cytoplasm [13]. This is 
further consistent with the observation that although many 
cell types have a distinctive pattern of cell distribution of 
IGF-II/M6P receptors the majority of these receptors are 
reported to be localized intracellularly and only a minor 
part at the cell surface 13,251. 
The IGF-II/M6P receptor in membrane associated en- 
vironments was further examined as to the mannose 6- 
phosphate recognition site. using D-mannose 6-phosphate 
and P-galactosidase, an acid hydrolyse with phosphoman- 
nosy1 residues which serve as ligands for binding to the 
receptor [2,3]. We found that very low concentrations of 
P-galactosidase (20 nM for half-maximal inhibition of 
IGF-II binding) inhibited the ‘251-IGF-II binding. Thus, 
P-galactosidase inhibits binding of t2?-IGF-II to the IGF- 
II/M6P by binding to the receptor with high affinity. We 
found the same concentration of /3-galactosidase required 
for half-maximal inhibition as observed by binding of 
highly purified /3-galactosidase to pure IGF-II/M6P re- 
ceptor [4,5,26]. The ‘251-IGF-II binding was studied at 
three fixed P-galactosidas,e concentrations in order to re- 
veal changes in ‘251-IGF-Il binding affinities. Our data did 
not reflect any correlation between dissociation constant 
and inhibiting concentrations of P-galactosidase (Fig. 3). 
Likewise, we did not find any changes in affinity of 
1251-IGF-II for the receptor irrespective of M6P concentra- 
tion as shown by the stimulation experiments (Fig. 5). This 
may support the assumption that the M6P sites and the 
IGF-II site do not interact directly. By contrast, Kiess et al. 
[5] detected by Scatchard analysis of IGF-II binding to 
pure IGF-II/M6P receptors isolated from rat placenta in 
the presence and absence of P-galactosidase that /3- 
galactosidase decreased the binding affinity for IGF-II (Kd 
0.26 nM versus 1.0 nM in the presence of 57 nM p- 
galactosidase). It has been reported that the IGF-II/M6P 
receptor monomer has one binding site for P-galactosidase 
and two binding sites for M6P [26]. The binding sites of 
M6P has been further localized to domains l-3 and 7-11 
of the extracytoplasmic region [27]. The inhibition by 
/3-galactosidase could be explained by assuming that p- 
galactosidase binds to one (or both?) of the two M6P 
recognition sites on the receptor. When /3-galactosidase 
with its phosphomannosyl residue is bound to the M6P 
binding sites, the binding of IGF-II may be impeded by 
sterical hindrance of the P-galactosidase molecule or alter- 
natively by conformational changes of the receptor on 
P-galactosidase binding. The exact IGF-II binding site of 
the IGF-II/M6P receptor still has to be defined, but it has 
been suggested that the IGF-II binds to a sequence local- 
ized close to the domain 13 which is near to the transmem- 
brane spanning region. An explanation of the M6P effect 
could be that M6P displaces other compounds carrying a 
mannose 6-phosphate residue including P-galactosidase at 
the M6P receptor binding sites as demonstrated here. Fig. 
4 shows that although M6P reversed the inhibitory effect 
of /3-galactosidase it did not reverse it completely. The 
1251-IGF-II binding did not reach the level obtained in 
absence of P-galactosidase in the incubation medium. So 
M6P reverses the inhibitory effect of P-galactosidase to 
various extent dependent on the receptor preparation pro- 
cedure, a phenomenon also observed by others [5]. Thus, 
the interactions between /3-galactosidase and M6P still 
remains unclear and probably other approaches have to be 
used. 
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